109 related articles for article (PubMed ID: 16679089)
21. Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry.
Gitt AK; Juenger C; Jannowitz C; Karmann B; Senges J; Bestehorn K
Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):438-44. PubMed ID: 19369876
[TBL] [Abstract][Full Text] [Related]
22. Management of metabolic syndrome: statins.
Xydakis AM; Ballantyne CM
Endocrinol Metab Clin North Am; 2004 Sep; 33(3):509-23, vi. PubMed ID: 15262294
[TBL] [Abstract][Full Text] [Related]
23. Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment.
Malmström RE; Ostergren J; Jørgensen L; Hjemdahl P;
J Intern Med; 2009 Nov; 266(5):457-66. PubMed ID: 19549094
[TBL] [Abstract][Full Text] [Related]
24. Lipid-lowering effect of preoperative statin therapy on postoperative major adverse cardiac events after coronary artery bypass surgery.
Thielmann M; Neuhäuser M; Marr A; Jaeger BR; Wendt D; Schuetze B; Kamler M; Massoudy P; Erbel R; Jakob H
J Thorac Cardiovasc Surg; 2007 Nov; 134(5):1143-9. PubMed ID: 17976441
[TBL] [Abstract][Full Text] [Related]
25. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency.
Chonchol M; Cook T; Kjekshus J; Pedersen TR; Lindenfeld J
Am J Kidney Dis; 2007 Mar; 49(3):373-82. PubMed ID: 17336698
[TBL] [Abstract][Full Text] [Related]
26. Statins for asymptomatic middle cerebral artery stenosis: The Regression of Cerebral Artery Stenosis study.
Mok VC; Lam WW; Chen XY; Wong A; Ng PW; Tsoi TH; Yeung V; Liu R; Soo Y; Leung TW; Wong KS
Cerebrovasc Dis; 2009; 28(1):18-25. PubMed ID: 19420918
[TBL] [Abstract][Full Text] [Related]
27. Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin.
Schick BA; Laaksonen R; Frohlich JJ; Päivä H; Lehtimäki T; Humphries KH; Côté HC
Clin Pharmacol Ther; 2007 May; 81(5):650-3. PubMed ID: 17329991
[TBL] [Abstract][Full Text] [Related]
28. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
29. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.
Hanefeld M; Marx N; Pfützner A; Baurecht W; Lübben G; Karagiannis E; Stier U; Forst T
J Am Coll Cardiol; 2007 Jan; 49(3):290-7. PubMed ID: 17239709
[TBL] [Abstract][Full Text] [Related]
30. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome.
Devaraj S; Chan E; Jialal I
J Clin Endocrinol Metab; 2006 Nov; 91(11):4489-96. PubMed ID: 16968805
[TBL] [Abstract][Full Text] [Related]
31. Treatment of hypercholesterolemia in patients with metabolic syndrome: how do different statins compare?
Knopp RH; Paramsothy P
Nat Clin Pract Endocrinol Metab; 2006 Mar; 2(3):136-7. PubMed ID: 16932272
[No Abstract] [Full Text] [Related]
32. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
[TBL] [Abstract][Full Text] [Related]
33. An evaluation of low-dose simvastatin in achieving LDL goal: a retrospective chart review.
Schnee DM; Bogdanski L; Zaiken K; McCloskey WW
Manag Care Interface; 2007 May; 20(5):53-7. PubMed ID: 17626594
[TBL] [Abstract][Full Text] [Related]
34. Angiotensin II type 1 receptor expression in polymorphonuclear leukocytes from high-risk subjects: changes after treatment with simvastatin.
Marino F; Guasti L; Cosentino M; Ferrari M; Rasini E; Maio RC; Cimpanelli MG; Cereda E; Crespi C; Simoni C; Restelli D; Venco A; Lecchini S
J Cardiovasc Pharmacol; 2007 May; 49(5):299-305. PubMed ID: 17513949
[TBL] [Abstract][Full Text] [Related]
35. Metabolic syndrome does not impact survival in patients treated for coronary artery disease.
Shah B; Kumar N; Garg P; Kang E; Grossi E; Lorin JD; Schwartzbard AZ; Mass H; Danoff A; Sedlis SP
Coron Artery Dis; 2008 Mar; 19(2):71-7. PubMed ID: 18300742
[TBL] [Abstract][Full Text] [Related]
36. How to reach LDL targets quickly in patients with diabetes or metabolic syndrome.
Leiter LA; Martineau P; de Teresa E; Farsang C; Gaw A; Gensini G; Langer A;
J Fam Pract; 2008 Oct; 57(10):661-8. PubMed ID: 18842192
[TBL] [Abstract][Full Text] [Related]
37. Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome.
Chyrchel M; Rakowski T; Rzeszutko L; Legutko J; Dziewierz A; Dubiel JS; Dudek D
Kardiol Pol; 2006 Dec; 64(12):1357-62; discussion 1363. PubMed ID: 17206539
[TBL] [Abstract][Full Text] [Related]
38. The effects of improved metabolic risk factors on bone turnover markers after 12 weeks of simvastatin treatment with or without exercise.
Jiang J; Boyle LJ; Mikus CR; Oberlin DJ; Fletcher JA; Thyfault JP; Hinton PS
Metabolism; 2014 Nov; 63(11):1398-408. PubMed ID: 25151031
[TBL] [Abstract][Full Text] [Related]
39. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
[TBL] [Abstract][Full Text] [Related]
40. Effect of metabolic syndrome on prognosis and clinical characteristics of revascularization in patients with coronary artery disease.
Hu R; Ma CS; Nie SP; Lü Q; Kang JP; Du X; Zhang Y; Gao YC; He LQ; Jia CQ; Liu XM; Dong JZ; Liu XH; Chen F; Zhou YJ; Lü SZ; Wu XS
Chin Med J (Engl); 2006 Nov; 119(22):1871-6. PubMed ID: 17134585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
